NY-ESO-1/GLA-SE cancer vaccine (Immune Design)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameNY-ESO-1/GLA-SE cancer vaccine (Immune Design)
Drug Alias NameCancer vaccine NY-ESO-1G-305IDG-305IDCG-305
ClassificationBiologics > Antigen > Tumor antigenBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsBreast Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmune Design
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmune Design
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsBreast Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A